目的 探討雙參龍膠囊聯(lián)合苯磺酸氨氯地平治療血管痙攣性心絞痛的臨床療效。方法 選取2017年3月—2021年3月在天津市寧河區(qū)醫(yī)院心血管內(nèi)科住院治療的142例血管痙攣性心絞痛患者，根據(jù)隨機(jī)數(shù)字法將142例血管痙攣性心絞痛患者分為對(duì)照組和治療組，每組各71例。對(duì)照組患者口服苯磺酸氨氯地平片，5 mg/次，1次/d。治療組患者在對(duì)照組的基礎(chǔ)上口服雙參龍膠囊，4粒/次，3次/d。兩組患者連續(xù)服用藥物5 d。觀察兩組臨床療效，比較兩組臨床癥狀緩解時(shí)間及心絞痛發(fā)作情況、血清炎性因子水平。結(jié)果 治療后，治療組患者總有效率是98.59%，顯著高于對(duì)照組的85.92%（P＜0.05）。治療后，治療組患者臨床出現(xiàn)的胸悶、氣短、心前區(qū)疼痛緩解時(shí)間均顯著短于對(duì)照組（P＜0.05）。治療后，兩組心絞痛持續(xù)時(shí)間、發(fā)作次數(shù)均較治療前顯著降低（P＜0.05），且治療后治療組心絞痛持續(xù)時(shí)間、心絞痛發(fā)作次數(shù)低于對(duì)照組（P＜0.05）。治療后，兩組患者血清白細(xì)胞介素6（IL-6）、腫瘤壞死因子α（TNF-α）、可溶性血管細(xì)胞黏附因子-1（sVCAM-1）水平均較治療前顯著降低，但血清基質(zhì)金屬蛋白酶9（MMP-9）水平升高（P＜0.05）；且治療后，治療組患者血清炎性因子水平改善優(yōu)于對(duì)照組（P＜0.05）。結(jié)論 雙參龍膠囊聯(lián)合苯磺酸氨氯地平治療血管痙攣性心絞痛具有較好的臨床療效，可有效改善患者臨床癥狀，并能降低心絞痛發(fā)作次數(shù)和炎性反應(yīng)，值得臨床借鑒與推廣。

Objective To investigate the curative effect of Shuangshenlong Capsules combined with amlodipine besylate in treatment of vasospastic angina.Methods A total of 142 patients with vasospastic angina who were hospitalized in the Department of Cardiovascular Medicine, Ninghe District Hospital of Tianjin, from March 2017 to March 2021 were selected. According to the random number method, 142 patients with vasospastic angina were divided into control group and treatment group, with 71 cases in each group. Patients in the control group were po administered with Amlodipine Besylate Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Shuangshenlong Capsules on the basis of the control group, 4 grains/time, three times daily. Two groups of patients continued to take drugs for 5 d. The clinical efficacy of the two groups were observed, and the relief time of clinical symptoms, angina pectoris attack, and the level of serum inflammatory factors were compared between the two groups.Results After treatment, the total effective rate in treatment group was 98.59%, which was significantly higher than 85.92% in control group (P < 0.05). After treatment, the relief time of chest tightness, shortness of breath and precardiac pain in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the duration of angina pectoris and the frequency of angina pectoris in the treatment group were significantly lower than those before treatment (P < 0.05), and the duration of angina pectoris and the frequency of angina pectoris in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of serum interleukin-6 (IL-6), tumor necrosis factor α (TNF-α) and soluble vascular cell adhesion factor-1 (sVCAM-1) in two groups were significantly decreased compared with before treatment, but the level of serum matrix metalloproteinase 9 (MMP-9) was increased (P < 0.05). After treatment, the level of serum inflammatory factors in the treatment group was better than that in the control group (P < 0.05).Conclusion Shuangshenlong Capsules combined with amlodipine besylate has a good clinical effect in treatment of vasospastic angina, and can effectively improve the clinical symptoms of patients, and reduce the frequency of angina attack and inflammatory reaction, which is worthy of clinical reference and promotion.

R972

河北省中醫(yī)藥管理局中醫(yī)藥科研項(xiàng)目（2021396）